Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials

In the era of the Internet of Things (IoT), drug developers can potentially access a wealth of real-world, participant-generated data that enable better insights and streamlined clinical trial processes. Protection of confidential data is of primary interest when it comes to health data, as medical...

Descripción completa

Detalles Bibliográficos
Autores principales: Angeletti, Fabio, Chatzigiannakis, Ioannis, Vitaletti, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308650/
https://www.ncbi.nlm.nih.gov/pubmed/30487435
http://dx.doi.org/10.3390/s18124175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308650/
https://www.ncbi.nlm.nih.gov/pubmed/30487435
http://dx.doi.org/10.3390/s18124175

Ejemplares similares